Helicobacter Pylori Eradication: Survey conducted by the Colombian Association of Gastroenterology
DOI:
https://doi.org/10.22516/25007440.19Keywords:
Survey, helicobacter pylori, Maastricht IV ConsensusAbstract
The aim of this study is to present the results of an online survey about strategies and schemes used by members of the Colombian Association of Gastroenterology (ACG - Asociación Colombiana de Gastroenterología) to diagnose and eradicate Helicobacter pylori infections in light of the Maastricht IV/ Florence Consensus Report. Information was prospectively collected between December 2013 and May 2014 through a virtual questionnaire on the official website of the Colombian Association of Gastroenterology (ACG).
The survey was answered by 114 physicians, of whom 60 (52%) were internists and gastroenterologists located in major cities. The results show that 61% (n = 71) of respondents adhere to the recommendations of Maastricht for the first line eradication scheme and 66% (n = 76) adhere to the consensus’ recommendations for the second line scheme. Another aspect of the survey that should be highlighted is that, in contrast to the recommendations of Maastricht that monoclonal fecal antigens or the urea breath test be used for assessment of eradication, the diagnostic test favored by 63% (n = 72) of respondents was upper endoscopy plus a biopsy with Giemsa staining. This is probably because of availability and costs in our country.
The results of the survey show treatment schemes for eradication of Helicobacter preferred by the professionals who responded, and allow us to evaluate the acceptability of, and adherence to, the recommendations
on treatment regimens of the consensus. This includes contrasts such as following up eradication treatment by endoscopy rather than the methods recommended by the consensus.
Downloads
Languages:
enReferences
Goodwin CS, Worsley BW. Microbiology of Helicobacter pylori. Gastroenterol Clin North Am 1993;22:5-19.
Marshall BJ. History of the discovery of C. pylori. In: Campylobacter Pylori in Gastritis and Peptic Ulcer Disease, Blaser MJ (Ed), Igaku-Shoin, New York 1989. p7.
Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;1:1311.
Oleastro M, Ménard A. The role of Helicobacter pylori Outer membrane proteins in adherence and pathogenesis. biology. 2013;2:1110-34.
Costa F, D’Elios M. Management of Helicobacter pylori infection. Anti Infect Ther 2010;8:887-92.
Otero W, Trespalacios A, Otero E. Helicobacter pylori: Current treatment. An important challenge for gastroente- rology. Rev Col Gastroenterol 2009;24:280-92.
Trespalacios A, Otero W, Mercado M. Helicobacter pylori resistance to metronidazole, clarithromycin and amoxicillin in Colombian patients. Rev Col Gastroenterol 2010;25:31-8.
McColl KE. Helicobacter pylori infection. N Engl J Med 2010;362:1597-604.
Watari J, Chen N, Amenta PS, Fukui H, Oshima T, Tomita T, et al. Helicobacter pylori associated chronic gastritis, cli- nical syndromes, precancerous lesions, and pathogenesis of gastric cancer development. World J Gastroenterol 2014;20:5461-73.
Garza-González E, Pérez-Pérez GI, Maldonado-Garza HJ,
Bosques-Padilla FJ. A review of Helicobacter pylori diagno- sis, treatment, and methods to detect eradication. World J Gastroenterol 2014;20:1438-49.
Gutiérrez O, Aponte D, Páramo D, Sabbag LC, Angel LA, Cardona H, et al. Seroprevalencia y factores de riesgo aso- ciados con la infección por Helicobacter pylori en niños. Rev Col Gastroenterol 2001;16:19-22.
Bravo LE, Cortés A, Carrascal E, Jaramillo R, García LS, Bravo PE, et al. Helicobacter pylori: patología y prevalencia en biopsias gástricas en Colombia. Col Med 2003;34:124-31.
Banic M, Franceschi F, Babić Z, Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection. Helicobacter. 2012;17(Suppl 1):49-55.
Chen BF, Xu X, Deng Y, Ma SC, Tang LQ, Zhang SB, et al. Relationship between Helicobacter pylori infection and serum interleukin-18 in patients with carotid atherosclero- sis. Helicobacter. 2013;18:124-8.
Bang CS, Baik GH. Attempts to enhance the eradication rate of Helicobacter pylori infection. World J Gastroenterol 2014;20:5252-62.
Malfertheiner P, Venerito M,. Selgrad M. Helicobacter pylori infection: selected aspects in clinical Management. Curr Opin Gastroenterol 2013;29:669-75.
O’Connor A, Molina-Infante J, Gisbert JP, O’Morain C. Treatment of Helicobacter pylori infection 2013. Helicobacter 2013;18(Suppl 1):58-65.
GrahamDY,FischbachL.Helicobacterpyloritreatmentinthe era of increasing antibiotic resistance. Gut 2010;59:1143-53.
Goh KL, Chan WK, Shiota S, Yamaoka Y. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter 2011;16(Suppl 1):1-9.
Dattoli VC, Veiga RV, da Cunha SS, Pontes-de-Carvalho LC, Barreto ML, Alcântara-Neves NM. Seroprevalence and potential risk factors for Helicobacter pylori infection in Brazilian children. Helicobacter. 2010;15:273-8.
Fialho AM, Braga AB, Braga Neto MB, Carneiro JG, Rocha AM, Rodrigues MN, et al. Younger siblings play a major role in Helicobacter pylori transmission among children from a low-income community in the Northeast of Brazil. Helicobacter 2010;15:491-6.
TrebelK,Rolle-KampczykU,RichterM,KindlerA,Richter T, Schlink U. A rigorous small area modelling-study for the Helicobacter pylori epidemiology. Sci Total Environ 2010;408:3931-42.
Epplein M, Signorello LB, Zheng W, Peek RM Jr, Michel A, Williams SM, et al. Race, African ancestry, and Helicobacter pylori infection in a low-income United States population. Cancer Epidemiol Biomarkers Prev 2011;20:826-34.
Arnold M, Moore SP, Hassler S, Ellison-Loschmann L, Forman D, Bray F. The burden of stomach cancer in indigenous populations: A systematic review and global assessment Gut. 2014;63:64-71.
Gómez M, Otero W, Caminos JE. Gastric cancer in young patients in Colombia. Rev Col Gastroenterol 2012;27:166-72.
Asaka M, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010;15:1-20.
Ma JL, Zhang L, Brown LM, Li JY, Shen L, Pan KF, et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst 2012;104:488-92.
Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, et al. China Gastric Cancer Study Group. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: A randomized controlled trial. JAMA 2004;291:187-94.
Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, et al. Meta-analysis: Can Helicobacter pylori era- dication treatment reduce the risk for gastric cancer? Ann Intern Med 2009;151:121-28.
Osborn JF, Cattaruzza MS, Ferri AM, De Angelis F, Renzi D, Marani A, et al. How long will it take to reduce gastric can- cer incidence by eradicating Helicobacter pylori infection? Cancer Prev Res (Phila) 2013;6:695-700.
Shiota S, Yamaoka Y. Management of Helicobacter pylori. Med Rep 2010;15:2. pii:20.
Bae SE, Jung HY, Kang J, Park YS, Baek S, Jung JH, et al. Effect of Helicobacter pylori eradication on metachronous recurrence after endoscopic resection of gastric neoplasm. Am J Gastroenterol 2014;109:60-7.
Bang CS, Baik GH. Attempts to enhance the eradication rate of Helicobacter pylori infection. World J Gastroenterol 2014;20:5252-62.
Lansdorp-Vogelaar L, Sharp L. Cost-effectiveness of scree- ning and treating Helicobacter pylori for gastric cancer pre- vention. Best Pract Res Clin Gastroenterol 2013;27:933-47.
Yang JC, Lu CW, Lin CJ. Treatment of Helicobacter pylori infection: Currentstatus and future concepts. World J Gastroenterol 2014;14;20:5283-93.
Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013;62:34-42.
Wu TS, Hu HM, Kuo FC, Kuo CH. Eradication of Helicobacter pylori infection. Kaohsiung J Med Scienc 2014;30:167e1-72.
Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection the Maastricht IV/Florence Consensus Report. Gut 2012;61:646-64.
Otero Regino W. La importancia de cultivar Helicobacter pylori. Rev Col Gastroenterol 2013;28:87-92.
Rimbara E, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol 2011;8:79-88.
Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143-53.
Hunt RH, Xiao SD, Megraud F, Leon-Barua R, Bazzoli F, van der Merwe S, et al. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis 2011;20:299-304.
Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infec- tion. Am J Gastroenterol 2007;102:1808-25.
Camargo MC, García A, Riquelme A, Otero W, Camargo CA, Hernández-García T, et al. The problem of Helicobacter pylori resistance to antibiotics: A systematic review in Latin America. Am J Gastroenterol 2014;109:485-95.
Chuah SK, Tsay FW, Hsu PI, Wu DC. A new look at anti-Helicobacter pylori therapy. World J Gastroenterol. 2011;17:3971e5.
Gómez M, Otero W, Gutiérrez O. Tratamiento de la infec- ción gástrica con Helicobacter pylori: encuesta a un grupo de médicos generales y especialistas en Colombia/Treatmet of gastric infection with H. pylori. Acta Med Col 2011;26: 273-9.
Breuer T, Sudhop T, Goodman KJ. How do practicing cli- nicians manage Helicobacter pylori-related gastrointestinal diseases in Germany? Helicobacter. 1998;1:1-8.
Shirin H, Birkenfeld S, Shevah O, Levine A, Epstein J, Boaz M, et al. Application of Maastricht 2-2000 Guidelines for the Management of Helicobacter pylori Among Specialists and Primary Care Physicians in Israel: Are We Missing the Malignant Potential of Helicobacter pylori? J Clinic Gastroenterol 2004;4:322-5.
Ghanaei FM, Joukar F, Soati M, Gharib S, et al. Knowledge and Practice of General Practitioners and Internists about Helicobacter pylori infection in Guilan, Iran. Middle East J Diges Diseases 2011;3:119-25.
Downloads
Published
How to Cite
Issue
Section
License
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
Los autores/as ceden sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación en esta revista.
Los contenidos están protegidos bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
